<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=384506&amp;fmt=gif">
Skip to content
    March 22, 2023

    PhoreMost Enhances Drug Discovery Process with CDD Vault

    CDD Press Release Logo

    PhoreMost Enhances Drug Discovery Process with CDD Vault

    Burlingame, CA - March 22, 2023 - Collaborative Drug Discovery, Inc. (CDD), developer of the research data management platform, CDD Vault, announced today that PhoreMost Ltd., a leading drug discovery biotechnology company developing a pipeline of first-in-class targets in oncology and targeted protein degraders, has adopted CDD Vault for managing drug discovery research data. The move is part of PhoreMost's ongoing commitment to data quality, innovation and improvement, and aims to streamline data management and reporting within its drug discovery processes.

    CDD Vault is a secure, hosted platform that allows organizations to manage and share data from drug discovery projects in a single, centralized repository. It features tools for data management, querying, collaboration, and visualization, as well as integrations with other software commonly used in the biotech industry. With CDD Vault, PhoreMost will be able to manage all aspects of its drug discovery projects in one place, from data collection and analysis to project management and reporting.

    PhoreMost's adoption of CDD Vault is the latest in a series of strategic moves the company has made to advance its drug discovery processes. In the last year, the Cambridge, UK based company has also expanded its headquarters into a new state-of-the-art facility, invested in new equipment and technology, and has grown its research and development team.

    PhoreMost's SITESEEKER® platform, based on the Company's core proprietary 'Protein Interference' (PROTEINi) technology, probes the entire proteome to systematically unmask new and unanticipated druggable sites, directly linking them to useful therapeutic functions. In addition to developing an internal pipeline, including multiple oncology programs and six progams targeting novel E3 ligases for targeted protein degradation, PhoreMost has used its SITESEEKER platform to establish broad collaborations with biopharma partners.

    Dr. Rich Boyce, SVP Drug Discovery, PhoreMost, said: "We are delighted to adopt CDD Vault as our primary platform for managing our drug discovery projects. The platform will allow us to easily collaborate and share data across teams, streamline our workflow, and ultimately improve the drug discovery process. By adopting CDD Vault, we will be able to accelerate data management across in-house projects and collaborations with our partners."

    "PhoreMost is a leading player in the biotech industry, especially in PROTACs, and we are thrilled to have them using CDD Vault," added Dr. Barry Bunin, CEO, CDD. "We are delighted to support their research efforts to discover new treatments for patients in need. By providing an easy-to-use and secure solution for managing drug discovery data, we are empowering PhoreMost to make better decisions faster and effectively bring new treatments to market."

    About PhoreMost 

    PhoreMost has developed a next-generation phenotypic screening platform called SITESEEKER® that can discern the best new targets for future therapy and crucially, how to drug them, which has the potential to significantly increase the diversity and affordability of novel therapeutics for cancer and other unmet diseases. Based on the Company's core proprietary 'Protein Interference' technology, SITESEEKER® systematically unmasks cryptic druggable sites across the entire human genome and directly links them to useful therapeutic functions in a live-cell context. Using this platform, PhoreMost is building a pipeline of novel drug discovery programmes aimed at addressing a range of unmet diseases.

    For more information visit https://www.phoremost.com/

    Media enquiries

    PhoreMost:
    Dr Ben Rutter
    Zyme Communications
    E-mail: ben.rutter@zymecommunications.com
    Tel: +44 (0)7920 770 935

    About Collaborative Drug Discovery, Inc.

    CDD's (www.collaborativedrug.com) flagship product, "CDD Vault®", is used to manage chemical registration, structure-activity relationships (SAR), and securely scale collaborations. CDD Vault® is a hosted database solution for secure management and sharing of biological and chemical data. It lets you intuitively organize chemical structures and biological study data, and collaborate with internal or external partners through an easy to use web interface. Available modules within CDD Vault include Activity & Registration, Visualization, Inventory, and ELN.

    A complete list of more than 60 publications and patents from CDD can be found online on our resources page at https://www.collaborativedrug.com/publications-and-resources/.



    Media Contact: Barry Bunin, Ph.D., Collaborative Drug Discovery, marketing@collaborativedrug.com.

    Tag(s): CDD Blog , News

    Other posts you might be interested in

    View All Posts
    CDD Vault Updates
    4 min   February 26, 2024
    CDD Vault Update (February 2024): New Models for LogD and LogP, Similarity Scores in Deep Learning, and Updated GET Users Call
    Read More
    CDD Blog
    2 min   February 14, 2024
    CDD Receives Malaria Antibody Data Management Grant
    Read More
    CDD Blog
    8 min   February 9, 2024
    Drug Discovery Industry Roundup with Barry Bunin — February 9, 2024
    Read More